Westmount Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Westmount Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$301K	Hold	1,000	–	–	0.07%	212
2026 Q1	$331K	Hold	1,000	–	–	0.08%	194
2025 Q4	$398K	Hold	1,000	–	–	0.1%	159
2025 Q3	$461K	Hold	1,000	–	–	0.12%	143
2025 Q2	$326K	Hold	1,000	–	–	0.09%	180
2025 Q1	$270K	Hold	1,000	–	–	0.08%	196
2024 Q4	$235K	Hold	1,000	–	–	0.07%	192
2024 Q3	$275K	Sell	1,000 -5	-0.5%	-$1.3K	0.08%	175
2024 Q2	$245K	Buy	+1,005	New	+$159K	0.08%	180
2023 Q2	–	Sell	-1,000	Closed	-$200K	–	189
2023 Q1	$200K	Hold	1,000	–	–	0.09%	172
2022 Q4	$238K	Buy	+1,000	New	+$213K	0.12%	152

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Westmount Partners's ALNY Position: Q2 2026 in Review

Westmount Partners held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,000 shares worth $301K. The position accounts for 0.07% of the portfolio, ranked #212.

Westmount Partners first reported a position in ALNY in Q4 2022 and has held it in 11 quarters since. The position peaked at $461K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Westmount Partners held 1,000 shares of Alnylam Pharmaceuticals worth $301K as of Q2 2026.
Westmount Partners left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.07% of Westmount Partners's portfolio in Q2 2026, its #212 holding.
Westmount Partners first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Westmount Partners's Alnylam Pharmaceuticals position peaked at $461K in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Westmount Partners's 13F filing for Q2 2026, filed 7 Jul 2026.